Nebivolol Ratiopharm (Nebivolol Hydrochloride)

Nebivolol Hydrochloride, the active ingredient in Nebivolol Ratiopharm, is a beta blocker presented as a tablet for oral use. It treats hypertension and heart failure in adult patients.

GNH USA supplies Nebivolol Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic blocker used in cardiovascular conditions.

Hypertension: lowers systemic blood pressure by reducing cardiac output and promoting vasodilation. Heart failure: improves left‑ventricular systolic function and reduces symptoms in chronic heart failure. Left ventricular systolic dysfunction: supports cardiac performance and may delay disease progression.

Nebivolol is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or tiredness. - Nausea or mild gastrointestinal upset. - Bradycardia: heart rate slower than normal. - Peripheral edema: swelling of ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Marked hypotension leading to fainting. - Bronchospasm in patients with asthma or COPD. - Allergic reactions such as rash, itching, or angio‑edema. - Hepatic dysfunction with elevated liver enzymes. - Worsening heart failure symptoms.

Before initiating therapy, clinicians should assess cardiovascular status and comorbid conditions.

Monitor blood pressure: ensure adequate control without excessive drop. Assess cardiac function: especially in patients with existing heart failure. Use caution in asthma/COPD: β‑blockade may precipitate bronchospasm. Adjust dose in renal/hepatic impairment: consider reduced clearance. Avoid abrupt discontinuation: taper to prevent rebound hypertension. Store below 25°C: keep in the original pack, protect from moisture.

Nebivolol may interact with several drug classes; careful review is advised.

Major Interactions (Avoid): - Combined use with other β‑blockers: risk of excessive bradycardia. - Calcium channel blockers verapamil or diltiazem: may increase plasma levels. - Potent CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): can raise nebivolol concentrations. - Clonidine withdrawal: may cause severe hypertension. - Antihypertensive agents causing additive hypotension.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor for enhanced blood pressure reduction. - Diuretics: watch for electrolyte disturbances and volume depletion. - NSAIDs: may blunt antihypertensive effect. - Antiarrhythmic drugs (e.g., amiodarone): monitor cardiac rhythm. - Other antihypertensives: adjust dose as needed.